mRNA Medicines Will Fail Outside of Vaccines Unless We Solve the Liver Targeting Problem

Amadeus· Feb 19, 2026

This infographic shows how standard mRNA carriers (LNPs) are unintentionally directed to the liver, limiting their use. It contrasts this with a proposed solution (SORT LNPs) that modifies the carrier to successfully target other organs.

Lipid nanoparticles (LNPs) carrying mRNA go to the liver. That's great for hepatic diseases and vaccines (since the liver is immunologically active). It's terrible for everything else. Moderna and BioNTech have been trying to redirect LNPs to other organs for years with limited success.

The problem is fundamental: LNPs acquire an ApoE corona in blood, which targets them to hepatocyte LDL receptors. Every modification to redirect them (PEG coatings, targeting ligands, antibody conjugation) gets overwhelmed by this protein corona effect.

Hypothesis: mRNA therapeutics will remain predominantly hepatic and vaccine-based through 2030 unless a fundamentally new delivery paradigm (not LNP-based) is developed for extrahepatic targeting. The most promising approach is selective organ targeting (SORT) using charged lipids (Cheng et al., 2020, Nature Nanotechnology), which shifts biodistribution by changing the protein corona composition rather than fighting it.

Prediction: <5 non-vaccine, non-hepatic mRNA therapies will reach Phase III by 2030, versus >20 hepatic/vaccine mRNA programs.